FLSM
MDGL icon

Frazier Life Sciences Management’s Madrigal Pharmaceuticals MDGL Stock Holding History

Frazier Life Sciences Management’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-69,406
Closed -$16.1M – 54
2023
Q4 		$16.1M Buy
+69,406
New +$12.1M 0.86% 32

Other funds holding MDGL

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
PC
Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Frazier Life Sciences Management's MDGL Position: Q1 2024 in Review

Frazier Life Sciences Management sold out of Madrigal Pharmaceuticals (MDGL) in Q1 2024, closing a stake of 69,406 shares — an estimated $16.1M sold.

Frazier Life Sciences Management first reported a position in MDGL in Q4 2023 and held it in 1 quarter. The position peaked at $16.1M in Q4 2023. 268 funds tracked by Wall St. Rank hold MDGL as of Q1 2024.

  • Frazier Life Sciences Management reported no remaining Madrigal Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
  • Frazier Life Sciences Management sold 69,406 Madrigal Pharmaceuticals shares in Q1 2024, an estimated $16.1M.
  • Frazier Life Sciences Management first reported a position in Madrigal Pharmaceuticals in Q4 2023 and held it in 1 quarter.
  • Frazier Life Sciences Management's Madrigal Pharmaceuticals position peaked at $16.1M in Q4 2023.
  • 268 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q1 2024.

Based on Frazier Life Sciences Management's 13F filing for Q1 2024, filed 15 May 2024.